Pharvaris (PHVS) Other Non Operating Income (2020 - 2025)
Pharvaris' (PHVS) quarterly Other Non Operating Income came in at -$6.6 million in Q2 2025, down 335.69% YoY from $2.8 million in Q2 2024, and down 335.69% on a QoQ basis from $2.8 million in Q2 2024.
Analysis
Pharvaris (PHVS) Other Non Operating Income (2020 - 2025) Analysis & Trends
Pharvaris (PHVS) has 6 years of Other Non Operating Income data on file, last reported at -$6.6 million in Q2 2025.
- Quarterly Other Non Operating Income fell 335.69% year-over-year to -$6.6 million in Q2 2025, while the trailing twelve-month figure through Jun 2025 was -$3.2 million (down 120.36% YoY) and the FY2025 annual result came in at -$11.6 million, down 235.98% from the prior year.
- Other Non Operating Income eased to -$6.6 million in Q2 2025, from $2.8 million in the prior quarter.
- In the past five years, Other Non Operating Income ranged from a high of $12.3 million in Q2 2022 to a low of -$6.6 million in Q2 2025.
- A 5-year average of $2.7 million and a median of $3.3 million in 2024 frame the typical range for Other Non Operating Income.
- The widest YoY moves for Other Non Operating Income: up 20896.33% in 2021, down 13639.54% in 2021.
- Tracing PHVS's Other Non Operating Income over 5 years: stood at $4.8 million in 2021, then jumped by 158.56% to $12.3 million in 2022, then tumbled by 94.09% to $727085.7 in 2023, then jumped by 287.56% to $2.8 million in 2024, then tumbled by 335.69% to -$6.6 million in 2025.
- The last three Other Non Operating Income figures came in at -$6.6 million (Q2 2025), $2.8 million (Q2 2024), and $727085.7 (Q2 2023), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.31 Bn | 131.46 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.65 Bn | 77.66 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn |
| 4 | Moderna | 57.94 Bn | 52.80 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - |
| 6 | BeOne Medicines | 39.96 Bn | 34.86 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.16 Bn | 31.85 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn |
| 10 | Pharvaris | 2.14 Bn | 1.77 Bn | 85,072.10 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2025 | 2.74 Mn |
| Jun 30, 2025 | -5.55 Mn |
| Mar 31, 2025 | -4.05 Mn |
| Sep 30, 2024 | -3.93 Mn |
| Jun 30, 2024 | 5.08 Mn |
| Mar 31, 2024 | 628,156.10 |
| Dec 31, 2023 | -5.18 Mn |
| Sep 30, 2023 | 2.99 Mn |
| Mar 31, 2023 | -1.60 Mn |
| Dec 31, 2022 | 11,285.07 Bn |
| Mar 31, 2022 | 3.81 Mn |
| Dec 31, 2021 | -8.71 Mn |
| Sep 30, 2021 | 5.02 Mn |
| Jun 30, 2021 | -2.98 Mn |
| Mar 31, 2021 | 7.02 Mn |
| Dec 31, 2020 | 203,159.04 |
| Sep 30, 2020 | -147,572.54 |
| Jun 30, 2020 | -21,688.85 |
| Mar 31, 2020 | -33,750.73 |